The Real Cost of Smoking and Vaping Is Measured in Years of Life Lost
Share
For many individuals, smoking and vaping are viewed through the lens of habit, routine, or short term choice. The discussion often centers on cost, convenience, or alternatives, but this framing overlooks the most important reality. The true cost of nicotine use is not measured in daily consumption or even in long term expense. It is measured in the length and quality of a person’s life. When examined in this context, the impact becomes far more direct and far more consequential.
The scale of that impact is clearly established. The U.S. Centers for Disease Control and Prevention states that “Cigarette smoking remains the leading cause of preventable disease and death in the United States.”¹ It further reports that smoking “kills more than 480,000 Americans each year.”² On a global level, the World Health Organization confirms that tobacco use “kills more than 8 million people each year worldwide.”³ These figures are often cited in public health discussions, but their meaning extends beyond statistics. Each number represents individuals whose lives were shortened, often by many years, and whose time with family, work, and personal experiences was reduced as a result of long term nicotine exposure.
The human toll of smoking is not limited to the moment of death. In many cases, the more profound impact occurs gradually, over time, as health begins to decline. Individuals who smoke frequently experience reduced lung capacity, diminished physical endurance, and increased susceptibility to chronic conditions well before any terminal diagnosis is made. Daily activities become more difficult, energy levels decrease, and the ability to fully engage in life begins to narrow. This progression represents a loss not only of years, but of the quality within those years. It changes how people live long before it affects how long they live.
Vaping, while often perceived as a different category, operates within the same broader framework of nicotine dependence. The Centers for Disease Control and Prevention notes that “Most e-cigarettes contain nicotine,” and emphasizes that “Nicotine is highly addictive.”⁴ As a result, many users continue patterns of consumption that reinforce dependency over extended periods of time. While research continues to evaluate long term outcomes, the presence of ongoing nicotine exposure means that the behavioral and physiological cycle often remains intact. In addition, studies have identified that “E-cigarette aerosol can contain harmful substances, including nicotine, cancer causing chemicals, heavy metals such as nickel, tin, and lead, volatile organic compounds, and ultrafine particles.”⁵ These findings contribute to a broader concern that continued exposure over time may carry consequences that affect both longevity and overall health.
One of the most significant developments in recent years is the age at which nicotine use begins. According to the CDC, “E-cigarettes are the most commonly used tobacco product among U.S. youth.”⁶ When nicotine exposure starts earlier in life, the total duration of use increases, and the long term impact becomes more pronounced. Behavioral patterns formed at a younger age tend to persist, extending the cycle of dependency across decades. This effectively increases the number of years during which health may be affected and raises the likelihood of long term consequences that influence both lifespan and quality of life.
When viewed over time, nicotine use becomes a compounding factor rather than a single decision. Each day of continued use may appear insignificant in isolation, but the cumulative effect is substantial. The difference is not measured in individual moments, but in the aggregation of those moments over years. This is what ultimately shapes outcomes related to longevity. It is not a single event, but a sustained pattern that gradually influences how long a person lives and how fully they are able to experience that life.
As awareness of this reality increases, the conversation around smoking and vaping is beginning to shift. The focus is moving beyond short term behavior and toward long term outcomes. Individuals are increasingly considering not just whether they can quit, but what quitting represents in terms of reclaiming time, improving quality of life, and reducing the long term impact of dependency. This shift is also influencing how healthcare providers, employers, and public health systems approach nicotine use, with greater emphasis placed on reducing dependency rather than maintaining it in alternative forms.
Within this evolving landscape, new approaches are being developed to align with these broader objectives. Redwood Scientific Technologies is focused on advancing nicotine free oral thin film technologies through its TBX FREE and TBX VAPE FREE platforms. These technologies are designed to support smoking and vaping cessation without relying on continued nicotine intake, reflecting a growing interest in solutions that move beyond substitution and toward elimination. By focusing on both behavioral patterns and the removal of nicotine, Redwood’s approach is aligned with a broader shift toward improving long term human outcomes.
This positioning does not represent a claim of clinical effectiveness. It reflects an alignment with the direction in which both the problem and the market are moving. As the long term impact of nicotine use becomes more widely understood, the demand for approaches that address dependency at its source may continue to grow.
Ultimately, the issue is not defined by products or categories, but by time. The years a person is able to live, the quality of those years, and the difference between a life that is gradually limited and one that remains fully accessible over time. Smoking and vaping, when viewed in this context, are not simply habits. They are factors that influence how life is experienced and how long it endures. As that understanding becomes more central to the conversation, it is likely to shape both individual decisions and the future direction of the market itself.
Sources and References
- U.S. Centers for Disease Control and Prevention
https://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette-smoking-in-united-states.html - U.S. Centers for Disease Control and Prevention
https://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette-smoking-in-united-states.html - World Health Organization
https://www.who.int/news-room/fact-sheets/detail/tobacco - U.S. Centers for Disease Control and Prevention
https://www.cdc.gov/tobacco/e-cigarettes/health-effects.html - U.S. Centers for Disease Control and Prevention
https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html - U.S. Centers for Disease Control and Prevention
https://www.cdc.gov/tobacco/e-cigarettes/youth.html
About Redwood Scientific Technologies, Inc.
Redwood Scientific Technologies, Inc. is focused on developing innovative nicotine free technologies designed to help smokers transition away from combustible cigarettes and nicotine based products. The company’s TBX FREE and TBX VAPE FREE platforms are designed to address the behavioral and sensory aspects of smoking cessation while eliminating nicotine.
Redwood has previously achieved large scale commercial distribution of its oral thin film technologies and continues to advance new solutions designed for the global smoking cessation market. With more than 1 billion smokers worldwide and increasing regulatory pressure on both cigarettes and vaping products, demand for effective nicotine free alternatives continues to grow.
Additional information about Redwood Scientific Technologies can be found at
https://redwoodsci.com
Additional Company Disclosure
Redwood Scientific Technologies, Inc. is currently advancing the development of its nicotine free cessation technologies, including TBX FREE and TBX VAPE FREE. The company is in the process of completing required clinical validation through controlled research protocols.
Redwood’s products are not currently being marketed or sold. The company intends to complete a double blind placebo controlled efficacy study covering both product platforms prior to any commercial launch. These studies are designed to evaluate the effectiveness of the products in supporting smoking and vaping cessation and to provide data suitable for scientific publication.
Until those studies are completed and the company finalizes its clinical and regulatory strategy, Redwood Scientific Technologies does not offer these products for sale.
In addition, Redwood’s commercial strategy is structured as a business to business distribution model. The company does not sell products directly to end users or directly to consumers. Instead, Redwood intends to work through licensed distributors, healthcare partners, and institutional channels for future product distribution.
Forward Looking Statement Notice
Certain statements contained in this article constitute forward looking statements within the meaning of applicable securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward looking statements include, but are not limited to, statements regarding clinical studies, product development, regulatory strategy, commercialization plans, and market opportunities.
Readers and investors should not place undue reliance on forward looking statements, which speak only as of the date of publication.
This article is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities.